{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:22:15Z","timestamp":1777936935781,"version":"3.51.4"},"reference-count":28,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1134\/s1607672924701060","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T14:15:27Z","timestamp":1719929727000},"page":"291-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic"],"prefix":"10.1134","volume":"518","author":[{"given":"A. A.","family":"Akimova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. E.","family":"Banshchikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"Sizikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Mullagaliev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. A.","family":"Letyagina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. A.","family":"Ilina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. D.","family":"Kurochkina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. B.","family":"Ubshaeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. O.","family":"Omelchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. A.","family":"Chumasova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. S.","family":"Shkaruba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Korolev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"7533_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.47360\/1995-4484-2021-31-36","volume":"59","author":"B.S. Belov","year":"2021","unstructured":"Belov, B.S. and Leela, A.M., COVID-19 and rheumatology: a year later, Nauchcno-Pract. \n               Revmatol., 2021, vol. 59, no. 1, pp. 31\u201336. https:\/\/doi.org\/10.47360\/1995-4484-2021-31-36","journal-title":"Revmatol."},{"key":"7533_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"E.J. Williamson","year":"2020","unstructured":"Williamson, E.J., Walker, A.J., Bhaskaran, K., Bacon, S., Bates, Ch., Morton, C.E., Curtis, H.J., Mehrkar, A., Evans, D., Inglesby, P., Cockburn, J., Mcdonald, H.I., Mackenna, B., Tomlinson, L., Douglas, I.J., Rentsch,\u00a0Ch.T., Mathur, R., Wong, A.Y.S., Grieve, R., Harrison, D., Forbes, H., Schultze, A., Croker, R., Parry, J., Hester, F., Harper, S., Perera, R., Evans, S.J.W., Smeeth, L., and Goldacre, B., Factors associated with COVID-19-related death using OpenSAFELY, Nature, 2020, vol. 584, no. 7821, pp. 430\u2013436. https:\/\/doi.org\/10.1038\/s41586-020-2521-4","journal-title":"Nature"},{"key":"7533_CR3","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1016\/j.jinf.2020.05.065","volume":"81","author":"M. Liu","year":"2020","unstructured":"Liu, M., Gao, Ya., Zhang, Yu., Shi, Sh., Chen, Ya., and Tian, J., The association between severe or dead COVID-19 and autoimmune diseases: A systematic review and meta-analysis, J. Infect., 2020, vol. 81, no. 3, pp. e93\u2013e95. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.065","journal-title":"J. Infect."},{"key":"7533_CR4","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/annrheumdis-2020-217888","volume":"79","author":"K.M. D\u2019Silva","year":"2020","unstructured":"D\u2019Silva, K.M., Serling-Boyd, N., Wallwork, R., Hsu, T., Fu, X., Gravallese, E.M., Choi, H.K., Sparks, J.A., and Wallace, Z.S., Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US \u2018hot spot\u2019, Ann. Rheum. Dis., 2020, vol. 79, no. 9, pp. 1156\u20131162. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217888","journal-title":"Ann. Rheum. Dis."},{"key":"7533_CR5","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","volume":"79","author":"M. Gianfrancesco","year":"2020","unstructured":"Gianfrancesco, M., Hyrich, K.L., Al-Adely, S., et al., Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann. Rheum. Dis., 2020, vol. 79, no. 7, pp. 859\u2013866. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217871","journal-title":"Ann. Rheum. Dis"},{"key":"7533_CR6","doi-asserted-by":"publisher","first-page":"725226","DOI":"10.3389\/fmed.2021.725226","volume":"8","author":"Y. Zhu","year":"2021","unstructured":"Zhu, Y., Zhong, J., and Dong, L., Epidemiology and clinical management of rheumatic autoimmune diseases in the COVID-19 pandemic: a review, Front. Med. (Lausanne), 2021, vol. 8, p. 725226. https:\/\/doi.org\/10.3389\/fmed.2021.725226","journal-title":"Front. Med. (Lausanne)"},{"key":"7533_CR7","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00296-020-04699-x","volume":"40","author":"J. Loarce-Martos","year":"2020","unstructured":"Loarce-Martos, J., Garc\u00eda-Fern\u00e1ndez, A., L\u00f3pez-Guti\u00e9rrez, F., Garc\u00eda-Garc\u00eda, V., Calvo-Sanz, L., Del Bosque-Granero, I., Ter\u00e1n-Tinedo, M.A., Boteanu, A., Bachiller-Corral, J., and V\u00e1zquez-D\u00edaz, M., High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study, Rheumatol. Int., 2020, vol. 40, no. 12, pp. 2015\u20132021. https:\/\/doi.org\/10.1007\/s00296-020-04699-x","journal-title":"Rheumatol. Int."},{"key":"7533_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.26442\/00403660.2022.05.201502","volume":"94","author":"M.A. Korolev","year":"2022","unstructured":"Korolev, M.A., Letyagina, E.A., Sizikov, A.E., Bogoderova, L.A., Ubshaeva, Yu.B., Omelchenko, V.O., Akimova, A.A., Mullagaliev, A.A., Chumasova, O.A., and Kurochkina, Yu.D., Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs, Ter. Arkh., 2022, vol.\u00a094, no. 5, pp. 636\u2013641. https:\/\/doi.org\/10.26442\/00403660.2022.05.201502","journal-title":"Ter. Arkh."},{"key":"7533_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S2665-9913(21)00059-X","volume":"3","author":"J. Avouac","year":"2021","unstructured":"Avouac, J., Drumez, E., Hachulla, E., et al., COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study, Lancet Rheumatol., 2021, vol. 3, no. 6, pp. 419\u2013426. https:\/\/doi.org\/10.1016\/S2665-9913(21)00059-X","journal-title":"Lancet Rheumatol."},{"key":"7533_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.47360\/1995-4484-2021-239-254","volume":"59","author":"E.L. Nasonov","year":"2021","unstructured":"Nasonov, E.L., Lila, A.M., Mazurov, V.I., Belov, B.S., Karateev, A.E., Dubinina, T.V., Nikitinskaya, O.A., Baranov, A.A., Abdulganieva, D.I., Moiseev, S.V., and Zagrebneva, A.I., Coronavirus disease 2019 (COVID-19) and immune-mediated rheumatic diseases. Recommendations of the Association of Rheumatologists of Russia, Nauchcno-Pract. \n               Revmatol., 2021, vol. 59, no. 3, pp.\u00a0239\u2013254. https:\/\/doi.org\/10.47360\/1995-4484-2021-239-254","journal-title":"Revmatol."},{"key":"7533_CR11","unstructured":"Avdeev, S.N., Adamyan, L.V., Alekseeva, E.I., Bagnenko, S.F., Baranov, A.A., et al., Interim Guidelines: Prevention, Diagnosis and Treatment of Novel Coronavirus Infection (COVID-19)."},{"key":"7533_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/fcp.12695","volume":"36","author":"A. Dernoncourt","year":"2022","unstructured":"Dernoncourt, A., Schmidt, J., Duhaut, P., Liabeuf, S., Gras-champel, V., Masmoudi, K., Bennis, Yo., and Batteux, B., COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database, Fundam. Clin. Pharmacol., 2022, vol. 36, no. 1, pp. 199\u2013209. https:\/\/doi.org\/10.1111\/fcp.12695","journal-title":"Fundam. Clin. Pharmacol."},{"key":"7533_CR13","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-020-0451-z","volume":"16","author":"G. Schett","year":"2020","unstructured":"Schett, G., Manger, B., Simon, D., and Caporali, R., COVID-19 revisiting inflammatory pathways of arthritis, Nat. Rev. Rheumatol., 2020, vol. 16, no. 8, pp. 465\u2013470. https:\/\/doi.org\/10.1038\/s41584-020-0451-z","journal-title":"Nat. Rev. Rheumatol."},{"key":"7533_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/mco2.154","volume":"3","author":"Yu. Jiang","year":"2020","unstructured":"Jiang, Yu., Zhao, T., Zhou, X., Xiang, Yu., Gutierrez-castrellon, P., and Ma, X., Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions, MedComm, 2020, vol. 3, no. 3, p. 154. https:\/\/doi.org\/10.1002\/mco2.154","journal-title":"MedComm"},{"key":"7533_CR15","unstructured":"World Health Organization. A Living WHO Guideline on Drugs for COVID-19, 2022. \nhttp:\/\/apps.who.int\/iris. Accessed 2022."},{"key":"7533_CR16","unstructured":"National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, 2022. \nhttps:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed 2022."},{"key":"7533_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.47360\/1995-4484-2022-505-518","volume":"60","author":"E.L. Nasonov","year":"2022","unstructured":"Nasonov, E.L. and Feist, E., The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6), Nauchno-Prakt. \n               Revmatol., 2022, vol. 60, no. 5, pp. 505\u2013518. https:\/\/doi.org\/10.47360\/1995-4484-2022-505-518","journal-title":"Revmatol."},{"key":"7533_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.47360\/1995-4484-2021-384-393","volume":"59","author":"E.L. Nasonov","year":"2021","unstructured":"Nasonov, E.L. and Avdeeva, A.S., B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19), Nauchcno-Pract. \n               Revmatol., 2021, vol. 59, no. 4, pp. 384\u2013393. https:\/\/doi.org\/10.47360\/1995-4484-2021-384-393","journal-title":"Revmatol."},{"key":"7533_CR19","first-page":"609","volume":"14","author":"M.R. Lichinitser","year":"2002","unstructured":"Lichinitser, M.R. and Stepanova, E.V., New anticancer drugs based on monoclonal antibodies, Russ. Med. Zh., 2002, vol. 14, p. 609.","journal-title":"Russ. Med. Zh."},{"key":"7533_CR20","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00296-020-04699-x","volume":"40","author":"J. Loarce-Martos","year":"2020","unstructured":"Loarce-Martos, J., Garc\u00eda-Fern\u00e1ndez, A., L\u00f3pez-Guti\u00e9rrez, F., Garc\u00eda-Garc\u00eda, V., Calvo-Sanz, L., Del\u00a0Bosque-Granero, I., Ter\u00e1n-Tinedo, M.A., Boteanu, A., Bachiller-Corral, J., and V\u00e1zquez-D\u00edaz, M., High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study, Rheumatol. Int., 2020, vol. 40, no. 12, pp. 2015\u20132021. https:\/\/doi.org\/10.1007\/s00296-020-04699-x","journal-title":"Rheumatol. Int."},{"key":"7533_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.15690\/vsp.v12i1.557","volume":"12","author":"A.A. Baranov","year":"2013","unstructured":"Baranov, A.A., Alexeeva, E.I., Bzarova, T.M., Valieva, S.I., Denisova, R.V., Isaeva, K.B., Litvitskii, P.F., Mitenko, E.V., Sleptsova, T.V., Fetisova, A.N., Chistyakova, E.G., Taibulatov, N.I., Morev, S.Yu., and Karagulyan, N.A., Management protocol for patients with juvenile arthritis, Vopr. Sovrem. Pediatr., 2013, vol. 12, no. 1, pp. 37\u201356. https:\/\/doi.org\/10.15690\/vsp.v12i1.557","journal-title":"Vopr. Sovrem. Pediatr."},{"key":"7533_CR22","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/annrheumdis-2021-220418","volume":"80","author":"J.A. Sparks","year":"2021","unstructured":"Sparks, J.A., Wallace, Z.S., Seet, A.M., COVID-19 Global Rheumatology Alliance, A., et al., Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry, Ann. Rheum. Dis., 2021, vol. 80, pp. 1137\u20131146.","journal-title":"Ann. Rheum. Dis."},{"key":"7533_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.26442\/00403660.2020.12.200522","volume":"92","author":"V.N. Antonov","year":"2020","unstructured":"Antonov, V.N., Ignatova, G.L., Pribytkova, O.V., Sleptsova, S.S., Strebkova, E.A., Khudyakova, E.A., Simakov, A.I., Rabets, S.Yu., Tikhonova, E.P., Kurmaeva, D.Yu., Petrushin, M.A., Mashkov, A.S., Gayazova, E.V., Yasheva, I.V., Andreev, M.A., Khinov-ker,\u00a0V.V., Karpunin, A.Yu., and Berezhanskiy, B.V., Experience of olokizumab use in COVID-19 patients, Ter. Arkh., 2020, vol. 92, no. 12, pp. 148\u2013154. https:\/\/doi.org\/10.26442\/00403660.2020.12.200522","journal-title":"Ter. Arkh."},{"key":"7533_CR24","doi-asserted-by":"crossref","unstructured":"Bobkova, S.S., Zhukov, A.A., Protsenko, D.N., Samoylenko, V.V., and Tyurin, I.N., Comparative efficiency and safety of il-6 monoclonal antibody drugs in patients with severe new coronavirus infection COVID-19. Retrospective cohort study, Vestn. Intens. Ter. im. A.I. Saltanova, 2021, no. 1, pp. 69\u201376.","DOI":"10.21320\/1818-474X-2021-1-69-76"},{"key":"7533_CR25","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3899\/jrheum.121389","volume":"40","author":"K. Shimamoto","year":"2013","unstructured":"Shimamoto, K., Ito, T., Ozaki, Yo., Amuro, H., Tanaka, A., Nishizawa, T., Son, Yo., Inaba, M., and Nomura, Sh., Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis, J. Rheumatol., 2013, vol. 40, no. 7, pp. 1074\u20131081. https:\/\/doi.org\/10.3899\/jrheum.121389","journal-title":"J. Rheumatol."},{"key":"7533_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1136\/annrheumdis-2018-214704","volume":"78","author":"Ch.T. Berger","year":"2019","unstructured":"Berger, Ch.T., Rebholz-Chaves, B., Recher, M., Manigold, T., and Daikeler, T., Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses, Ann. Rheum. Dis., 2019, vol. 78, no. 7, pp. 1012\u20131014. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214704","journal-title":"Ann. Rheum. Dis."},{"key":"7533_CR27","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmv.25801","volume":"92","author":"P. Luo","year":"2020","unstructured":"Luo, P., Liu, Yi., Qiu, L., Liu, X., Liu, D., and Li, J., Tocilizumab treatment in COVID-19: A single center experience, J. Med. Virol., 2020, vol. 92, no. 7, pp. 814\u2013818. https:\/\/doi.org\/10.1002\/jmv.25801","journal-title":"J. Med. Virol."},{"key":"7533_CR28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.29001\/2073-8552-2018-34-1-107-117","volume":"34","author":"V.O. Omelchenko","year":"2019","unstructured":"Omelchenko, V.O., Letyagina, E.A., Korolev, M.A., and Pospelova, T.I., Atherosclerotic lesion of carotid arteries in rheumatoid arthritis and its association with cardiovascular risk factors, Sib. Zh. Klin. Exp. Med., 2019, vol. 34, no. 1, pp. 107\u2013117. https:\/\/doi.org\/10.29001\/2073-8552-2018-34-1-107-117","journal-title":"Sib. Zh. Klin. Exp. Med."}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924701060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672924701060","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672924701060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:17:02Z","timestamp":1773760622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672924701060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["7533"],"URL":"https:\/\/doi.org\/10.1134\/s1607672924701060","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"3 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors of this work declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}},{"value":"All studies were performed in accordance with the principles of biomedical ethics as outlined in the 1964 Declaration of Helsinki and its later amendments. The study protocol was approved by the local ethical committee of the Research Institute of Clinical and Experimental Lymphology\u2014a branch of the Federal Research Center Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences (Protocol no. 168 dated November 11, 2021). Each participant in the study provided a voluntary written informed consent after receiving an explanation of the potential risks and benefits, as well as the nature of the upcoming study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}}]}}